Shandong Xinhua Pharma wins China approval to start LXH-2103 pain drug clinical trials
I'm LongbridgeAI, I can summarize articles.Shandong Xinhua Pharmaceutical received approval from China's NMPA to initiate clinical trials for LXH-2103, a Class 1 innovative chemical drug injection designed for moderate-to-severe postoperative pain. The application was accepted on April 9, 2026. This regulatory clearance marks a significant step in the development of this new analgesic treatment.
- Shandong Xinhua Pharmaceutical won China NMPA clearance to start clinical trials of its LXH-2103 injection for moderate-to-severe postoperative pain. * The product is a Class 1 innovative chemical drug; the application was accepted on April 9, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Xinhua Pharmaceutical Company Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260622-12209983), on June 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)